Humana Inc: Form 10-Q for the period ended Sep 30, 2019
Filed with the SEC on Nov 6, 2019 and accepted by EDGAR at Nov 6, 2019, 14:57 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-07-01 to 2019-09-30 | $16.24bn | us-gaap:Revenues |
| Revenue | 9 months2019-01-01 to 2019-09-30 | $48.59bn | us-gaap:Revenues |
| Selling, general and administrative | 3 months2019-07-01 to 2019-09-30 | $1.89bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2019-01-01 to 2019-09-30 | $5.25bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2019-07-01 to 2019-09-30 | $868.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2019-01-01 to 2019-09-30 | $2.83bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2019-07-01 to 2019-09-30 | $62.0m | us-gaap:InterestExpense |
| Interest expense | 9 months2019-01-01 to 2019-09-30 | $184.0m | us-gaap:InterestExpense |
| Income tax | 3 months2019-07-01 to 2019-09-30 | $200.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2019-01-01 to 2019-09-30 | $684.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-07-01 to 2019-09-30 | $689.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months2019-01-01 to 2019-09-30 | $2.19bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-07-01 to 2019-09-30 | $5.14 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2019-01-01 to 2019-09-30 | $16.24 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2019-07-01 to 2019-09-30 | $5.16 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2019-01-01 to 2019-09-30 | $16.31 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2019-07-01 to 2019-09-30 | 134,025,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2019-01-01 to 2019-09-30 | 135,189,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2019-01-01 to 2019-09-30 | $4.77bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2019-01-01 to 2019-09-30 | $506.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months2019-01-01 to 2019-09-30 | $216.0m | us-gaap:PaymentsOfDividends |
| Share repurchases | 9 months2019-01-01 to 2019-09-30 | $1.01bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2019-09-30 | $5.53bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-09-30 | $20.32bn | us-gaap:AssetsCurrent |
| Total assets | At period end2019-09-30 | $29.18bn | us-gaap:Assets |
| Current liabilities | At period end2019-09-30 | $11.11bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-09-30 | $17.58bn | us-gaap:Liabilities |
| Long-term debt | At period end2019-09-30 | $5.37bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2019-09-30 | $699.0m | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2019-09-30 | $11.60bn | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2019-09-30 | 132,426,045 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000049071-19-000105. Last ingested by Listed: Nov 6, 2026, 14:15 ET. Listed shows no prices and gives no investment advice.